SNORA60: SNORA60 is an H/ACA box snoRNA that has been found to be hypermethylated in gene promoters, along with other genes, such as PRPF3, PPP2R5A, and ANGEL2, which predicts a lower probability of BCR and is positively correlated with recurrence time [PMC8366102]. It has also been identified as one of the snoRFs that showed enrichment in response to radiation in the female CER [PMC9624364]. SNORA60 is one of the well-defined genes found in the GeneCards - Human Genes Database and has been associated with DLBCL [PMC9052811]. It has also been included in a prognostic risk model for DLBCL patients along with SNORD1A and SNORA66 [PMC9939161]. SNORD1A and SNORA60 have higher expression levels in DLBCL tissues compared to SNORA66 [PMC9939161]. Additionally, up-regulation of SNORD1A and SNORA60 correlated with an unfavorable outcome in DLBCL patients [PMC9939161]. Limited literature exists on the clinical value of SNORA60 in tumors [PMC9939161]. Functional analysis has shown that it is associated with positive regulation of cellular catabolic process and mRNA transport [PMC7355415]. Furthermore, reduced expression of SNORA60 has been observed in prostate cancer compared to normal expression levels, suggesting its potential as a biomarker for disease progression [PMC2923618].